FDA Approves Higher Dose of Novo's Wegovy

The U.S. Food and Drug Administration has granted approval for a higher dosage of Novo Nordisk's popular weight-loss medication, Wegovy. This development comes under a new fast-track review program, indicating a streamlined process for significant medical advancements. The approval signifies a potential expansion of treatment options for individuals managing excess body weight, offering a new therapeutic avenue for patients seeking effective weight management solutions.